Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.
Lynch has more than 25 years experience serving in management positions in the biotechnology and pharmaceutical industries. Previously, he served as executive chairman of Avila (acquired by Celgene in 2012) and Stromedix (acquired by Biogen Idec in 2012). Lynch also served as CEO and CFO at ImClone Systems, which he led through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of Erbitux (cetuximab), a novel cancer treatment. Prior to that, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.